Skip Ribbon Commands
Skip to main content

Stand Up To Cancer Canada

Stand Up To Cancer Canada (SU2C Canada), a program of the Entertainment Industry Foundation Canada, aims to build broad support for a groundbreaking “translational” research model that can produce meaningful advances in cancer treatment.  With the goal of accelerating the pace at which new therapies get to patients, SU2C Canada will enable leading scientists in different disciplines from multiple institutions to work together.
On September 4, 2014, more than $109 million (CAD) was pledged in connection with the star-studded Stand Up To Cancer (SU2C) “roadblock” fundraising telecast in Canada and the U.S.  The $30 million (CAD) pledged in Canada will be used by SU2C Canada, and in some cases by collaborating organizations, to support joint research efforts utilizing the SU2C model and scientific oversight. These funds will support research by interdisciplinary, multi-institutional translational and clinical research Dream Teams. Dream Teams, composed of distinguished investigators, are responsible for conducting collaborative, novel, groundbreaking cancer research projects that address critical problems in patient care and are designed to deliver near-term patient benefit.  Funds pledged by the Canadian public during the telecast will stay in Canada to support the creation of collaborative research teams, as well as education and awareness programs conducted in Canada.
As the scientific partner of SU2C Canada, AACR International – Canada provides expert peer review, grants administration, and scientific oversight to the SU2C Dream Teams that seek to push forward innovative cancer research.
The review of the Dream Teams will be conducted via a rigorous yet rapid, flexible and transparent process led by a “Blue Ribbon” Canadian Scientific Advisory Committee (CSAC). The CSAC is composed of prominent researchers and is co-chaired by Nobel Laureate Phillip A. Sharp, PhD, Institute Professor at the David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT) and Alan Bernstein, OC, PhD, FRSC, President and CEO of the Canadian Institute for Advanced Research (CIFAR).

Français | ​English